

Supplementary Table S1: Serrated polyp subtypes and their association with BRAF V600E and KRAS mutations, CIMP-H status and MLH1, p16 and IGFBP7 methylation

Clinical, pathological & molecular features	All cases	BRAF mutant	KRAS mutant	CIMP-H	MLH1 methylation	p16 methylation	IGFBP7 methylation	IGFBP7 & p16 methylation
Serrated polyps	154	82 (53.25%)	40 (25.97%)	30 (19.48%)	8 (5.19%)	35 (22.73%)	62 (40.26%)	19 (12.34%)
BRAF mutant								
Serrated polyps	82	-	0	27 (32.93%)	7 (8.54%)	26 (31.71%)	43 (52.44%)	16 (19.51%)
HP	48	-	0	6 (12.5%)	1 (2.08%)	9 (18.75%)	20 (41.67%)	2 (4.17%)
GCHP	12	-	0	3 (25%)	0	3 (25%)	7 (58.33%)	1 (8.33%)
MVHP	36	-	0	3 (8.33%)	1 (2.78%)	6 (16.67%)	13 (36.11%)	1 (2.78%)
TSA	2	-	0	1 (50%)	0	0	1 (50%)	0
MP	4	-	0	2 (50%)	0	2 (50%)	2 (50%)	1 (25%)
SSA	28	-	0	18 (64.29%)	6 (21.43%)	15 (53.57%)	20 (71.43%)	13 (46.43%)
KRAS mutant								
Serrated polyps	40	0	-	0	0	3 (7.5%)	6 (15%)	1 (2.5%)
HP	35	0	-	0	0	3 (8.57%)	5 (14.29%)	1 (2.86%)
GCHP	30	0	-	0	0	2 (6.67%)	5 (16.67%)	1 (3.33%)
MVHP	5	0	-	0	0	1 (20%)	0	0
TSA	0	0	-	0	0	0	0	0
MP	2	0	-	0	0	0	1 (50%)	0
SSA	3	0	-	0	0	0	0	0
CIMP-H								
Serrated polyps	30	27 (90%)	0	-	6 (20%)	21 (70%)	21 (70%)	16 (53.33%)
HP	9	6 (66.67%)	0	-	0	6 (66.67%)	4 (44.44%)	3 (33.33%)
GCHP	4	3 (75%)	0	-	0	3 (75%)	2 (50%)	1 (25%)
MVHP	5	3 (60%)	0	-	0	3 (60%)	2 (40%)	2 (40%)
TSA	1	1 (100%)	0	-	0	0	1 (100%)	0
MP	2	2 (100%)	0	-	0	1 (50%)	2 (100%)	1 (50%)
SSA	18	18 (100%)	0	-	6 (33.33%)	14 (77.78%)	14 (77.78%)	12 (66.67%)

Supplementary Table S2: Association between CIMP status, BRAF V600E and KRAS mutations in all polyp types

Polyp type	All cases	CIMP-H cases	CIMP-H						CIMP-negative cases	CIMP-negative					
			KRAS		BRAF		KRAS/BRAF			KRAS		BRAF		KRAS/BRAF	
			Mut	Wild	Mut	Wild	Mut	Wild		Mut	Wild	Mut	Wild	Mut	Wild
SP	154	30 (19.48%)	0	30 (100%)	27 (90%)	3 (10%)	0	3 (10%)	124 (80.52%)	40 (32.26%)	84 (67.74%)	55 (44.35%)	69 (55.65%)	0	29 (23.39%)
HP	109	9 (8.26%)	0	9 (100%)	6 (66.67%)	3 (33.33%)	0	3 (33.33%)	100 (91.74%)	35 (35%)	65 (65%)	42 (42%)	58 (58%)	0	23 (23%)
GCHP	59	4 (6.78%)	0	4 (100%)	3 (75%)	1 (25%)	0	1 (25%)	55 (93.22%)	30 (54.55%)	25 (45.45%)	9 (16.36%)	46 (83.64%)	0	16 (29.09%)
MVHP	50	5 (10%)	0	5 (100%)	3 (60%)	2 (40%)	0	2 (40%)	45 (90%)	5 (11.11%)	40 (88.89%)	33 (73.33%)	12 (26.67%)	0	7 (15.56%)
TSA	3	1 (33.33%)	0	1 (100%)	1 (100%)	0	0	0	2 (66.67%)	0	2 (100%)	1 (50%)	1 (50%)	0	1 (50%)
MP	7	2 (28.57%)	0	2 (100%)	2 (100%)	0	0	0	5 (71.43%)	2 (40%)	3 (60%)	2 (40%)	3 (60%)	0	1 (20%)
SSA	35	18 (51.43%)	0	18 (100%)	18 (100%)	0	0	0	17 (48.57%)	3 (17.65%)	14 (82.35%)	10 (58.82%)	7 (41.18%)	0	4 (23.53%)
CA	63	1 (1.59%)	0	1 (100%)	1 (100%)	0	0	0	62 (98.41%)	11 (17.74%)	51 (82.26%)	0	62 (100%)	0	51 (82.26%)
TA	52	1 (1.92%)	0	1 (100%)	1 (100%)	0	0	0	51 (98.08%)	4 (7.84%)	47 (92.16%)	0	51 (100%)	0	47 (92.16%)
TVA	11	0	0	0	0	0	0	0	11 (100%)	7 (63.64%)	4 (36.36%)	0	11 (100%)	0	4 (36.36%)